Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, there was not statistical differences in both VEGF levels and angiogenic capacity in patients with low-grade gliomas and controls.
|
31624989 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nine radiomic features were selected to generate a VEGF-associated radiomic signature of diffuse gliomas based on the mRMR algorithm.
|
31639060 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the inhibiting efficacy of AAV2-VEGF-Trap for glioma.
|
30136881 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma.
|
30845704 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There was an upsurge in VEGF serum level as glioma grade increased.
|
31653130 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The low expression rates of Ki-67 and VEGF in patients with grade I-II brain glioma were significantly higher than in patients with grade III-IV glioma (p<0.05).
|
29745085 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FIR might increase the growth of glioma under TMZ treatment in rats possibly via increasing VEGF expression, but not HIF-1α expression.
|
31280210 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CBF determined by 3D-ASL correlates with VEGF expression in glioma and is an independent risk factor for OS in these patients.
|
30652410 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously confirmed the safety and immunogenicity of a vaccine treatment targeting tumor angiogenesis with synthetic peptides, for vascular endothelial growth factor receptor (VEGFR) epitopes in recurrent HGG patients.
|
30791546 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of Limb-Bud and Heart (LBH) promotes angiogenesis in human glioma via VEGFA-mediated ERK signalling under hypoxia.
|
31631037 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The binding of transcription factor SP1 with vascular endothelial cell growth factor A (VEGFA) promoter was inspected using chromatin immunoprecipitation (ChIP). circSCAF11 expression was found to be significantly upregulated in the glioma tissue specimens and cell lines.
|
31400609 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
If the CBV and CBF values of the non-enhanced glioma were higher, the grade of malignancy was higher (P<0.01), and the positive expression rate of VEGF was higher (P<0.01).
|
29366307 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The K<sup>trans</sup> derived from DCE-MRI can reflect the VEGF expression of high-grade gliomas but not the MVD.
|
29330968 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, [<sup>123</sup>I]-VEGF may provide relevant prognostic information in patients with glioma.
|
30062604 |
2018 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression.
|
30429891 |
2018 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The VEGF polymorphism rs833061 was strongly associated with increased risk for glioma (odds ratio = 164.85) and glioblastoma (odds ratio = 155.66), confirmed after Bonferroni correction.
|
29584591 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have shown that glioma stem cells (GSCs) are involved in tumor vascularization by secreting vascular endothelial growth factor (VEGF).
|
30107336 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the quantity of VEGF in the glioma microenvironment seems to be crucial for the participation of microglia/macrophages on tumor progression and should be considered for developing novel therapeutic approaches.
|
28948650 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutic efficacy of a synthetic epsin mimetic peptide in glioma tumor model: uncovering multiple mechanisms beyond the VEGF-associated tumor angiogenesis.
|
29357089 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical data have demonstrated that plerixafor (a reversible CXCR4 inhibitor) could inhibit glioma progression after anti-VEGF pathway inhibition.
|
29941486 |
2018 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, eIF4FD suppressed glioma vascularization via reductions in the expression of β‑catenin and vascular endothelial growth factor.
|
30066885 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that CYP4A inhibition by FLA-16 prolongs survival and normalizes vasculature in glioma through decreasing production of TAMs and EPCs-derived VEGF and TGF-β.
|
28602979 |
2017 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokines related to glioma risk (P ≤ .05) more than 10 years before diagnosis are sIL10RB, VEGF, beta-Catenin and CCL22.
|
28594935 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glioma stem cells (GSCs) are capable of forming vasculogenic mimicry (VM), an alternative microvascular circulation independent of VEGF-driven angiogenesis.
|
28812437 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two mechanisms of bevacizumab-induced MIF reduction were identified: (1) bevacizumab bound MIF and blocked MIF-induced M1 polarization of macrophages; and (2) VEGF increased glioma MIF production in a VEGFR2-dependent manner, suggesting that bevacizumab-induced VEGF depletion would downregulate MIF.
|
28218903 |
2017 |